# Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI

> **NCT05079451** · PHASE1 · WITHDRAWN · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** 3BNC117-LS
- **DRUG:** 10-1074-LS

## Key facts

- **NCT ID:** NCT05079451
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01-01
- **Primary completion:** 2024-01-15
- **Final completion:** 2024-02-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Protocol Withdrawal
- **Last updated:** 2023-09-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05079451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05079451, "Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05079451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*